Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.

Hyejee Ohm, Naveen S. Basappa, Mehul Gupta et al.|Journal of Clinical Oncology|2024

Cited by 0